Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Ultra VioletteUltra Violette Becomes First Brand in the US to Launch a Sunscreen Containing Newly FDA-Approved Filter BemotrizinolCult Australian suncare brand debuts Unblock Screen™ SPF 50, the first US sunscreen formulated with Bemotrizinol (BEMT), approved by the FDA in June 2026 — Ultra Violette, the cult Australian suncare brand known for pairing high-performance SPF with...
- Enliven Therapeutics, Inc.Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingEnliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from...
- Astellas Pharma Inc.Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines– Agreement supports commitment to patient access, affordability and innovation – — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our...
- Disc Medicine IncDisc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingDisc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.
- AN2 Therapeutics, Inc.AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingMENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco
- Adicet Bio, Inc.Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026.
- SealaskaInvesting in the Future by Upholding Traditional ValuesSealaska, the Alaska Native regional corporation for Southeast Alaska, is building a future rooted in Indigenous values. By growing businesses that improve ocean health around the world, Sealaska generates sustainable revenue that is reinvested in shareholders, communities, culture and...
- Greenway Greenhouse Cannabis CorporationGreenway Reports First Quarter Fiscal 2027 Financial ResultsGreenway Greenhouse Cannabis Corporation (CSE: GWAY) (OTCQB: GWAYF) ("Greenway" or the "Company"), a cultivator of high-quality greenhouse cannabis for the Canadian and international medical cannabis markets, today announced its unaudited...
- Zura Bio LimitedZura Bio to Participate in the Cantor Global Healthcare ConferenceHENDERSON, Nev., August 31, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference:
- Olema OncologyOlema Oncology to Participate in Upcoming Investor ConferencesOlema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
- Certain BlackRock Closed-End Funds Announce Estimated Sources of DistributionsCompanies: BlackRockNEW YORK, August 31, 2026--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE: BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE: BUI), BlackRock En
- Enovis Corporation DallasEnovis to Participate in the 2026 Wells Fargo Healthcare ConferenceEnovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.